Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series | Zendy

Tine Rosenberg | Zendy; Annette Dam Fialla | Zendy; Jens Kjeldsen | Zendy; Anette Drøhse Kjeldsen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series

Author(s) -

Tine Rosenberg,

Annette Dam Fialla,

Jens Kjeldsen,

Anette Drøhse Kjeldsen

Publication year - 2019

Publication title -

rhinology journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.275

H-Index - 57

eISSN - 1996-8604

pISSN - 0300-0729

DOI - 10.4193/rhin18.289

Subject(s) - medicine , bevacizumab , population , randomized controlled trial , surgery , dermatology , intensive care medicine , chemotherapy , environmental health

Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder, with a wide variety of clinical manifestations due to the presence of multiple arteriovenous manifestations. Severe bleeding from the gastrointestinal (GI) tract and/or epistaxis presents a significant problem in a subgroup of patients and systemic bevacizumab, an angiogenesis inhibitor, has been suggested to benefit these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research